We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Ablation System Destroys Uterine Fibroids

By HospiMedica International staff writers
Posted on 17 Apr 2013
A minimally invasive laparoscopic system delivers radiofrequency (RF) energy to obliterate uterine fibroids.

The Acessa System and procedure for the treatment of symptomatic uterine fibroids includes the RF Generator, which provides the energy needed for ablation and electrocautery to control bleeding common in the treatment of myomas, as well as continuous monitoring and real-time temperature control. More...
The system also includes the Acessa handpiece, which houses the control features for the RF generator interface, and the electrode array, which is deployed under ultrasound guidance; in smaller tissue volumes, it is not always necessary to deploy the electrode array.

Each electrode contains an internal thermocouple that allows continuous sampling of applied voltage, current, and temperatures from the thermocouples and other system parameters; the duration of the RF ablation is defined by a treatment algorithm based on the amount of deployment. . Patients typically go home the same day with little pain, and enjoy a rapid return to normal activities. After treatment, the damaged fibroid is reabsorbed by the surrounding tissue. The Acessa System is a product of Halt Medical (Brentwood, CA, USA), and has received regulatory approval in the European Union, the United States, Canada, and Mexico.

“Before the Acessa Technology, treatment involved cutting through layers of healthy tissue to gain access to the fibroids, or removing the uterus completely through a hysterectomy,” said associate professor Jay Berman, MD, of The Wayne State University Physician Group (WSUPG; Troy, MI, USA), who performed the first procedure on March 12, 2013. “Research shows the majority of women choose to suffer through their symptoms rather than undergo surgery.”

A uterine fibroid (leiomyomata) is a benign tumor that originates from the smooth muscle layer (myometrium) of the uterus. Fibroids are often multiple, and if the uterus contains too many to count, it is referred to as diffuse uterine leiomyomatosis. Fibroids are the most common benign tumors in females and are typically found during the middle and later reproductive years. While most are asymptomatic, they can grow and cause heavy and painful menstruation, painful sexual intercourse, and urinary frequency and urgency.

Related Links:

Halt Medical
Wayne State University Physician Group



Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Pressure Guidewire
SavvyWire
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.